With both Aurora and MEK inhibitory components, BI-847325 was shown to overcome acquired resistance to BRAF inhibitors in two-dimensional (2D) and three-dimensional in vitro settings and in in vivo models of melanoma (7). Here, MAP2K7 is linked to melanoma.